Background/Aims: A major challenge for current therapeutic strategies against ischemia/ reperfusion (I/R) is the lack of effective drugs. Considering luteolin enhances the activity of sarcoplasmic reticulum Ca 2+ -ATPase (SERCA2a) to improve the systolic/diastolic function of rat hearts and cardiomyocytes during the I/R process, we studied the regulatory function of the p38 MAPK pathway in this protective mechanism. Methods: Isolated cardiomyocytes and perfused hearts were separately divided into five groups and used to investigate I/R. The phosphorylation of p38 and phospholamban (p-PLB), the levels and activity of SERCA2a and the levels of proteins related to apoptosis were measured. Apoptotic cells were assessed using the TUNEL assay. Single-cell shortening, Ca 2+ transients, and the decay of the mitochondrial membrane potential (Δψm) were detected. Results: The p38 MAPK pathway was activated during the I/R process, and inhibiting it with SB203580 promoted p-PLB, which enhanced the activity of SERCA2a and relieved the calcium overload to promote the recovery of the Δψm and reduce cardiomyocyte apoptosis in I/R. Luteolin also suppressed the activation of the p38 MAPK pathway and showed cardioprotective effects during I/R injury. Conclusions: We conclude that luteolin enhances SERCA2a activity to improve systolic/diastolic function during I/R in rat hearts and cardiomyocytes by attenuating the inhibitive effects of the p38 pathway on p-PLB.
in patients suffering from myocardial ischemia is to achieve emergency reperfusion treatment by thrombolysis or opening the occluded vessels. Under these circumstances, the mortality from acute myocardial infarction is inversely related to myocardial salvage achieved by reperfusion [2] . However, considerable evidence gained from research from fundamental studies and clinical practice has demonstrated that reperfusion itself damages the myocardium, which is known as ischemia/reperfusion (I/R) injury. I/R injury includes reperfusion arrhythmia, myocardial systolic/diastolic dysfunction and no reflow, which is known to influence the effects of reperfusion therapy and is associated with higher mortality or worse prognosis. Therefore, in order to achieve the satisfactory therapeutic effects of myocardial ischemia, it is crucial to investigate the pathogenesis of I/R injury and search for new drugs.
Researchers discovered many mechanisms in I/R injury [3] [4] [5] [6] , calcium overload is the main cause of I/R injury [7] [8] [9] , but concrete evidence of the mechanisms involved has not yet been obtained. Calcium overload has many causes that lead to an increasing concentration of intracellular Ca
2+
, resulting in structural damage, functional or metabolic disorders, and sometimes cell apoptosis and death. The expression and activity of sarcoplasmic reticulum Ca
-ATPase (SERCA2a) is the main factor involved in calcium handling, as its dysfunction impairs myocardial systolic/diastolic function [10] . Phospholamban (PLB), a phosphoprotein that is mainly expressed in ventricular myocytes, is tightly related to SERCA2a activity; thus, it indirectly regulates the sarcoplasmic reticulum (SR) absorption of calcium during diastole [11, 12] . In its dephosphorylated state, PLB inhibits SERCA2a function, leading to reduced Ca 2+ re-uptake into the SR and cardiac contractility. By contrast, the phosphorylated form eliminates this inhibition.
The mitogen-activated protein kinase (MAPK) family includes extracellular signalregulated kinases (ERKs), c-Jun N-terminal kinases (JNKs), and p38-MAPKs [13] . Many studies have reported that JNK and ERK participate in myocardial I/R injury and pathological remodeling. In our previous studies, we also found that the JNK and ERK1/2 pathways were important in regulating cardiomyocyte contractility and decreasing apoptosis. The ERK1/2-PP1a pathway regulates the expression of phosphorylated PLB and SERCA2a [14] . The p38 MAPK pathway is another important pathway of the MAPK family, and p38 MAPK pathway inhibition could alleviate cardiomyocyte I/R injury and develop cardio-protective effects [15, 16] . In a recent randomized phase 2 trial in non-ST-segment elevation myocardial infarction, Newby et al. observed that the use of a novel p38 mitogen-activated protein kinase inhibitor, losmapimod, was well tolerated in non-ST-segment elevation myocardial infarction patients and might improve outcomes after acute coronary syndromes [17] . Kaikkonen et al. reported that negative p38α enhances SERCA2a function to improve cardiomyocyte contractility [18] . However, the exact mechanisms of the p38 MAPK pathway interacting with SERCA2a need to be clarified.
Luteolin (3',4,'5,'7'-tetrahydroxyflavone, Lut) is a natural, soluble flavone that is found in high levels in many plants, such as vegetables, fruits and herbs, and it exerts anti-tumor, antiinflammatory and anti-apoptotic activities [19] [20] [21] . Our preliminary experiments found that luteolin suppressed p38 MAPK activation when a pretreatment was administered before I/R. Due to the lack of effective solutions or drugs in clinical practice to alleviate I/R injury, we need to elucidate the relationship between the p38 MAPK pathway and SERCA2a, as well as the possible regulatory mechanism of luteolin pretreatment in the process of myocardial I/R.
The aim of this study was to use luteolin and a p38 mitogen-activated protein kinase inhibitor (SB203580) to determine whether SERCA2a is involved in and affects the negative cardiac function induced by p38 MAPK during myocardial I/R injury. The results of this study may lead to potential therapeutic targets for the prevention and treatment of myocardial I/R injury. Thus, we may clarify the mechanism underlying the cardio-protection of luteolin, which could be an effective drug for clinical application.
Materials and Methods

Animals and reagents
The experimental procedures on the animals were approved by the Xuzhou Medical University Animal Ethics Committee (permit number CMCACUC 2011-04-167). The animals were kept in a room with a controlled ambient temperature (22 ± 2°C) and humidity (50% ± 10%), with food and water ad libitum. All procedures were performed in accordance with the guidelines of the Animal Care and Use Committee of Xuzhou Medical University. Thirty clean-grade adult male Wistar rats (220-250 g, Animal Breeding Center of Xuzhou Medical University) were randomly assigned to the following groups (6 rats per group): 1. DMSO (DMSO); 2. I/R (I/R); 3. luteolin+I/R (Lut+I/R); 4. SB203580+I/R (SB+I/R); and 5. SB203580+luteolin+I/R (SB+Lut+I/R). DMSO was used to dissolve luteolin (purity>98%, Fluka, Milwaukee, WI, USA) and SB203580 (Cell Signaling Technology, Beverly, MA, USA) to a final concentration of <0.01% diluted with perfusate or culture medium, which had no effect on the heart [22] . All groups received DMSO.
Isolation of the cardiomyocytes
Single ventricular myocytes were obtained from the isolated rat hearts using type II collagenase (Gibco, Grand Island, NY, USA) as previously described [14, [23] [24] [25] 
Simulated I/R protocol and drug treatment
After the cardiac myocytes were equilibrated for 1 h, they were treated as follows: DMSO, the myocytes were incubated with DMSO alone for 18 h; I/R, the myocytes were treated with DMSO for 13 h, and then they were subjected to simulated ischemia for 3 h by substituting the cell medium for an 'ischemic buffer' containing (mM): 24 NaHCO 3 , 118 NaCl, 1.0 NaH 2 PO 4 , 2.5 CaCl 2 , 2 H 2 O, 20 sodium lactate, 1.2 MgCl 2 , 16 KCl and 102 deoxyglucose (pH 6.2) as described previously [26] . Next, the cells were incubated in a tri-gas incubator that was adjusted to 1% O 2 and 5% CO 2 at 37°C. After the simulated ischemia, the ischemic buffer was replaced by normal medium under normoxic conditions, and the cells were cultured for 2 h to simulate reperfusion. In the Lut+I/R group, before the simulated I/R, the myocytes were pretreated with luteolin (8 µM) for 12 h; in the SB+I/R group, the myocytes were treated with SB203580 (10 µM) for 1 h before the simulated I/R; in the SB + Lut + I/R group, the myocytes were pretreated with SB203580 for 1 h before the luteolin treatment, the same as Lut + I/R.
Isolated perfused heart preparation
Global I/R of the rat hearts was performed ex vivo according to our previous procedure [14] . Sodium heparin (1000 U/kg) and sodium pentobarbital (150 mg/kg) was administered to the experiment animals, then the rat hearts were excised and perfused, by Langendorff, with Krebs-Henseleit (KH) buffer solution containing (mM) 120 NaCl, 4.7 KCl, 1.2 KH 2 PO 4 , 1.2 MgSO 4 , 25 NaHCO 3 , 11 glucose and 1.25 CaCl 2, which was bubbled with 95% O 2 and 5% CO 2 at 37°C to maintain a pH of 7.4. The perfusion pressure was fixed at 80 mmHg.
After the hearts were equilibrated, the different groups were treated as follows: DMSO, the hearts were perfused with DMSO and KH buffer for 3.5 h; I/R, the isolated hearts were perfused with KH buffer for 1 h and then subjected to 30 min without the KH solution to simulate ischemia, which was followed by reperfusion with KH solution for 2 h; Lut + I/R, the isolated hearts were perfused with the KH buffer for 30 min before pretreatment with luteolin (40 µM) for 30 min, and then the I/R procedure was applied; SB + I/R, SB203580 (10 µM) was administered to the isolated hearts for 30 min, which had been treated with KH buffer for 30 min, followed by the I/R procedure; and SB + Lut + I/R, the hearts were administered SB203580 (10 µM) for 30 min before treatment with luteolin and then were treated as the Lut + I/R group. 
Assessment of apoptosis
Apoptotic cells were assessed using a terminal deoxynucleotidyl transferase-mediated dUTP nick endlabeling (TUNEL) kit (Roche, Basel, Kanton Basel-Stadt, Switzerland). After reperfusion, the isolated rat hearts were immersed in 4% paraformaldehyde overnight before being paraffin-embedded for sectioning. At least 3 slices and >10 fields were observed randomly, with each viewed field containing >50 cells from each group, by light microscopy (20× objective). Moreover, the nuclei of the cardiac myocytes were stained by 4', 6-diamidino-2-phenylindole (DAPI). Only the nuclei of the apoptotic cells were stained brown by the TUNEL method, whereas all of the nuclei were stained blue with DAPI. The percentage of apoptotic cardiac myocytes was the TUNEL-positive cardiomyocytes / the total number of counted cells.
Measurement of cell shortening and re-lengthening
Only distinct edges of rod-shaped cardiomyocytes were used to evaluate contractile function. The mechanical properties of single cardiomyocytes were examined using the SoftEdge MyoCam ® system (IonOptix, Milton, MA, USA) [27] . Briefly, under an inverted microscope (40x objective; IonOptix, Milton, MA, USA), the cardiac myocytes were stimulated with an electrical field with a frequency of 0.5 Hz. At least 30 cardiomyocytes in each group were detected. A single myocyte was shown on the monitor of a computer using an IonOptix MyoCam camera. The IonOptix SoftEdge software was used to image cell shortening and re-lengthening. The following parameters were recorded to measure these changes: the resting cell length, the peak shortening amplitude (PS), the time-to-peak shortening (TPS), the time-to-90% re-lengthening (TR90), and the maximum velocity of shortening and re-lengthening (± dL/dt). The contraction of the myocyte had to be stable for at least 5 min before the above indices were recorded.
Intracellular Ca 2+ transient measurements The intracellular Ca
2+ changes reflect the Ca-handling. Intracellular calcium was detected using a dual-excitation fluorescence photomultiplier system (IonOptix, Milton, MA, USA) [28] . Briefly, the myocytes were loaded with a Fura-2/AM (0.5 μM) solution for 10 min, and the fluorescence signal of Fura-2 was detected using an IonOptix fluorescence system (IonOptix, Milton, MA, USA). After subtracting the background fluorescence, the 340 nm and 380 nm ratio was analyzed offline using the SoftEdge MyoCam ® system (IonOptix, Milton, MA, USA). The fluorescence emission was detected from 480 to 520 nm, and the quantitative change in Fura-2 fluorescence intensity (FFI) was obtained from the FFI ratio at the 2 wavelengths. Regarding the baseline FFI, the ΔFFI (340/380) reflected the resting intracellular Ca 2+ level, the electrical stimulation-increased intracellular Ca 2+ levels and the intracellular Ca 2+ transient attenuation rate. The single exponential Tau was presented as an indicator of intracellular Ca 2+ clearance.
Detection of the decay of the mitochondrial membrane potential (Δψm)
Cardiac mitochondria were isolated from rats using the method previously described by Palmer et al. [29] Briefly, mitochondria were isolated by differential centrifugation from heart homogenates. Proteolytic treatment of the homogenate with Nagarse (3 mg/g tissue) was used to release the mitochondria from myofibrils. All steps of the isolation were performed on ice or at 4°C.
The differences of Δψm were detected by JC-1 staining (KaiJi Bio, Nanjing, Jiangsu, China), which is a sensitive fluorescent probe and a cationic lipid fluorescent dye according to its dual emission characteristics. JC-1 spontaneously forms complexes (JC-1 aggregation) at high ΔΨm in normal cells and emits an intense red fluorescence. However, JC-1 remains in the monomeric form at low ΔΨm in apoptotic cells and emits only green fluorescence. A prepared mitochondria suspension extracted from fresh myocardial tissues was incubated in JC-1 solution (5 μg/ml) for 20 min at 37°C before being rinsed twice with JC-1 buffer. The ratio of the red and green fluorescence was calculated to give a ΔΨm value. The percentage of cells with low mitochondrial Δψm was measured by flow cytometry (Becton Dickinson, Franklin Lakes, NJ, USA). The red fluorescence intensity was detected in the FL-1 channel and the green in the FL-2 channel, with the Q3 region enclosing the low mitochondrial ΔΨm population.
Measurement of SERCA2a activity
SERCA vesicles were obtained as previously described for the measurement of its activity [30] , which was detected using an inorganic phosphorus colorimetric method with an Ultramicro-ATPase assay kit (Jiancheng, Nanjing, Jiangsu, China). Briefly, this test includes an enzymatic and phosphorus reaction based
Results
Effect of luteolin on the expression of p-p38 MAPK, p-PLB and SERCA2a protein expression and SERCA2a activity after I/R
Western blotting indicated that, when compared with the DMSO group, the p38 MAPK pathway was markedly activated in the I/R group (P < 0.001), while p-PLB and SERCA2a protein expression was decreased (P < 0.001). By contrast, the activation of the p38 MAPK pathway was suppressed in the SB + I/R, Lut + I/R and SB + Lut + I/R groups in comparison with the I/R group (P < 0.01, P < 0.05, and P < 0.01, respectively). However, p-PLB and SERCA2a protein expression was partially reversed in the SB+I/R group (P < 0.05) and in the Lut + I/R and SB + Lut + I/R groups (both P < 0.01). There was no significant difference between the SB + I/R and SB + Lut + I/R groups (P > 0.05; Fig. 1a, b, c) .
After the simulated I/R process, the activity of SERCA2a markedly decreased compared with the DMSO group (1.93 ± 0.12 μmol Pi/mg/h vs 6.90 ± 0.26 μmol Pi/mg/h, P < 0.01). The SB+I/R group showed increased activity (3.43 ± 0.27 μmol Pi/mg/h vs 1.93 ± 0.12 μmol Pi/ mg/h, P < 0.05), and the activity of the Lut + I/R and SB + Lut + I/R groups was significantly increased compared with the DMSO group (4.87 ± 0.27 and 5.47 ± 0.29 μmol Pi/mg/h vs 1.93 ± 0.12 μmol Pi/mg/h, all P < 0.01). The SB + Lut + I/R group had a higher SERCA2a activity than the Lut + I/R group, but this difference was not significant (Fig. 1d) .
Effects of luteolin on I/R-induced apoptosis
Compared with the DMSO group, I/R clearly accelerated the apoptosis of cardiomyocytes (25.63 ± 0.59% vs 8.57 ± 0.38%, P < 0.01). The SB+I/R group partially decreased apoptosis (20.17 ± 0.46% vs 25.63 ± 0.59%, P < 0.05) compared with the I/R group. There was no difference between the effect in the Lut+I/R and SB+Lut+I/R groups (14.37 ± 0.41% vs 12.73 ± 0.44%, P > 0.05) on I/R-induced apoptosis (Fig. 2a, b, c) . The results are expressed as the mean ± SEM, n = 3. *P < 0.05, **P < 0.01 versus DMSO;
# P < 0.05 versus I/R; (P < 0.05) and the Lut + I/R and SB + Lut + I/R groups (both P < 0.01). However, no significant difference was found between the Lut + I/R and SB + Lut + I/R groups (Fig. 3a, b, c) .
Effect of luteolin on shortening/re-lengthening and the intracellular calcium transient of cardiomyocytes subjected to I/R
After the simulated I/R, the shortening/re-lengthening (Fig. 4a ) and the intracellular calcium transients (Fig. 4b) of the cardiomyocytes were measured. There was no significant difference among all groups in resting cell length, TPS and baseline FFI (P > 0.05). I/R markedly decreased the peak shortening (P < 0.001), ± dl/dt (P < 0.001) and the ΔFFI (P < 0.001) and prolonged the TR90 (P < 0.001) and the Tau (P < 0.001) compared with the DMSO group. In comparison with the I/R group, pretreatment with SB203580 alone reversed the above indices (P < 0.05), as did pretreatment with luteolin alone and pretreatment with SB203580 plus luteolin (P < 0.01). The pretreatment with SB203580 plus luteolin seemed to be better than the pretreatment with luteolin alone, but this difference was not significant (P > 0.05).
Influence of luteolin on ΔΨm of the different groups
After the simulated I/R process, ΔΨm clearly decreased (7.58 ± 0FF.55% vs 30.83 ± 0.73%, P<0.01). The SB + I/R group exhibited increased ΔΨm compared with the DMSO group (21.63 ± 0.76% vs 30.83 ± 0.73%, P < 0.05). The SB + Lut + I/R group had a higher ΔΨm than the Lut+I/R group, but this difference was not significant (14.00 ± 0.70% vs 16.43 ± 0.72%, P >0 .05) (Fig. 5) . 
Discussion
The mechanism of the p38 MAPK pathway on SERCA2a after I/R Myocardial I/R injury is a common and complex clinical phenomenon for which calcium overload is not only one of the mechanisms but also the result of a pathological process in I/R injury that causes cardiomyocyte death. As a critical SR protein regulating calcium release, storage and reuptake by the cardiomyocytes, SERCA2a is vital for maintaining intracellular calcium at a steady state to regulate cardiac systolic/diastolic function [31] . Increasing evidence shows that the expression and activity of SERCA2a decreases markedly after I/R, although the mechanism is unclear. The I/R process induces the dephosphorylation of PLB, which inhibits SERCA2a activity and causes an imbalance between SR Ca 2+ uptake and release, promoting mitochondrial calcium overload and leading to a considerable loss of cardiomyocytes .
In the initial part of this experiment, we found that the p38 MAPK pathway was markedly activated during I/R, which increased the expression of p-p38 MAPK; pretreatment with Lut before I/R suppressed the activation of the p38 MAPK pathway, which decreased p-p38 MAPK expression. These results showed that the cardioprotective effects of Lut were closely associated with the p38 MAPK pathway. The same result was found by Yu et al.; their study showed that I/R injury significantly enhanced p-p38 MAPK, p-ERK1/2 and p-JNK expression levels, and Lut pretreatment (10, 40, or 70 mg/kg) in rats significantly inhibited p-p38 MAPK, which was dependent on the concentration of Lut. [32] Our data provide crucial evidence of the mechanism of p38 MAPK on SERCA2a activity after I/R. The p38 MAPK pathway was obviously activated after I/R and induced a diastolic intracellular calcium increase, but it did not change the systolic intracellular calcium, which resulted in diastolic calcium overload accompanied by a decrease in p-PLB, SERCA2a levels, SERCA2a activity and cardiomyocyte contractility. However, pretreatment with SB203580 before I/R suppressed the activation of the p38 MAPK pathway, and these I/R-induced changes were partially reversed, from which we inferred that the p38 MAPK pathway participates in the process of I/R. Inhibiting the activation of p38 MAPK increased the phosphorylation of PLB and the natural protein of SERCA2a, leading to a loss of the inhibition of SERCA2a and an enhancement of SERCA2a activity, which increased the release and reuptake of SR calcium to alleviate the calcium overload, thereby improving the myocardial excitation-contraction coupling. Thus, PLB is the main target of the p38MAPK pathway to regulate SERCA2a activity.
The cardio-protection of Lut is produced by regulating the p38 MAPK pathway and then interacting on SERCA2a
The protective effects of Lut on cardiovascular disease have been widely studied. Hertog et al. [33] found that routine consumption of flavonoids such as Lut reduces the incidence Fig. 6 . Lut enhances SERCA2a activity and inhibits apoptosis through p38 MAPK signaling. Lut, like the p38-activated protein kinase inhibitor SB203580, suppresses the activation of p38 MAPK after I/R, which increases p-PLB and enhances the activity of SERCA2a, resulting in relief of the calcium overload and a strengthening of the calcium transient. Mitochondrial membrane potential and functional recovery after p38 MAPK pathway inhibition by Lut reduce the apoptosis of the cardiomyocytes. of myocardial infarction. Lut is cardioprotective against I/R injury, which is mediated by the PI3K/Akt, JNK, ERK and caspase pathways [34] . In previous experiments, we found that Lut had anti-apoptotic effects and improved myocardial contractile function after I/R through the PI3K/Akt, ERK1/2 and JNK pathways and that SERCA2a protein expression was significantly reduced in a rat myocardial I/R model but rebounded significantly after Lut pretreatment [23] [24] . However, the effect of Lut on the I/R cardiomyocyte calcium transient and the mechanism of its regulation of SERCA2a need elucidation. Our recent work demonstrated that Lut presented a similar function as SB203580, which, when administered before I/R, downregulated p-p38 MAPK and reversed the negative inotropic effect and the negative chronotropic calcium transient of I/R. PLB is the key protein regulated by Lut, which enhances the activity of SERCA2a and accelerates calcium recycling and release from the SR. This, in turn, lowers the diastolic calcium concentration and relieves the calcium overload to encourage excitation-contraction coupling in the myocardium. These effects improve the systolic/diastolic function in the I/R rat myocardium.
An excess of calcium accumulating in the mitochondria causes an overload, which damages the respiratory chain, decreases ATP synthesis, increases the release of ROS, and promotes the formation of the mitochondrial permeability transition pore, resulting in mitochondrial dysfunction, cell apoptosis and finally death [35] . Our results confirm that the destruction of the mitochondrial transmembrane potential and the increased apoptosis and necrosis of cardiomyocytes during I/R can be prevented or reduced by SB203580 or Lut, which was mediated by suppressing the activation of the p38 MAPK pathway.
In conclusion, from the above results, an activated p38 MAPK pathway after I/R is involved in regulating SERCA2a activity and the calcium transients, resulting in not only poor cardiac systolic/diastolic function but also cardiomyocyte apoptosis and necrosis. The cardioprotective effect of Lut against I/R injury is closely associated with the p38 MAPK pathway, which operates in two ways (Fig. 6) . First, like the p38-activated protein kinase inhibitor SB203580, Lut suppresses the activation of p38 MAPK after I/R, which increases p-PLB and enhances the activity of SERCA2a, resulting in relief of the calcium overload and a strengthening of the calcium transient, thereby promoting myocardial excitationcontraction coupling and showing positive inotropic and positive chronotropic actions. Second, Lut promotes mitochondrial membrane potential and functional recovery, reducing the apoptosis and necrosis of the cardiomyocytes. These two aspects directly or indirectly improve the cardiac systolic/diastolic function of I/R hearts. Similar to the function of p38-activated protein kinase inhibitor, Lut may have a potential value in the treatment of ischemic heart disease.
Further, this study and our previous studies demonstrate that the protective effect of Lut arises from regulating the PI3K/Akt and MAPK pathways; these pathways increase p-PLB expression, which relieves the inhibition of SERCA2a. Therefore, it is possible for Lut to target PLB through different pathways to protect the myocardium against I/R injury by enhancing SERCA2a activity, which would thereby improve the prognosis and long-term survival of patients suffering from I/R injury if these effects can be translated to humans.
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